# Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma

> **NCT02526823** · PHASE4 · UNKNOWN · sponsor: **Shandong Provincial Hospital** · enrollment: 360 (estimated)

## Conditions studied

- Lymphoma, Non-Hodgkin;Hodgkin Disease

## Interventions

- **DRUG:** R-CHOP/CHOPE or ABVD chemotherapy regimen
- **DRUG:** R-CDOP/CDOPE or DBVD chemotherapy regimen

## Key facts

- **NCT ID:** NCT02526823
- **Lead sponsor:** Shandong Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-08
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2019-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02526823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02526823, "Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02526823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*